Roche expands hepatitis diagnostics portfolio
Almost 300 million people globally have chronic hepatitis B
Almost 300 million people globally have chronic hepatitis B
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market
The Oradox brand introduced a range of revolutionary products designed to elevate the standard of oral care
Evinova will operate as a separate health-tech business within AstraZeneca
Decision on EU marketing authorisation expected for momelotinib by early 2024
Emphasizes the need for a collective effort on bolstering resilience across economies, societies, healthcare systems, education systems and infrastructure
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
Likmez oral suspension is the first and only FDA-approved liquid option for patients with adherence hurdles such as dysphagia, difficulty swallowing
Subscribe To Our Newsletter & Stay Updated